标题
Immune Checkpoint Inhibitors: Basics and Challenges
作者
关键词
-
出版物
CURRENT MEDICINAL CHEMISTRY
Volume 26, Issue 17, Pages 3009-3025
出版商
Bentham Science Publishers Ltd.
发表日期
2017-08-07
DOI
10.2174/0929867324666170804143706
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- SHP-1: the next checkpoint target for cancer immunotherapy?
- (2016) H. Angharad Watson et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Advances in immunotherapy for melanoma
- (2016) Jason M. Redman et al. BMC Medicine
- Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity
- (2016) Akiko Nagase-Zembutsu et al. CANCER SCIENCE
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Skin self-examination and long-term melanoma survival
- (2016) Lisa E. Paddock et al. MELANOMA RESEARCH
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- PD-1 says goodbye, TIM-3 says hello
- (2016) Diana Romero Nature Reviews Clinical Oncology
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. ONCOLOGIST
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- (2016) R. D. Dorand et al. SCIENCE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice
- (2016) Susan P. Foy et al. PLoS One
- Excluding T Cells: Is β-Catenin the Full Story?
- (2015) Siwen Hu-Lieskovan et al. CANCER CELL
- PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
- (2015) Nisha Nagarsheth et al. CANCER RESEARCH
- Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
- (2015) D. Di Mitri et al. CLINICAL CANCER RESEARCH
- Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
- (2015) P. Johnson et al. CLINICAL CANCER RESEARCH
- Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma
- (2015) Laurence Albiges et al. EUROPEAN JOURNAL OF CANCER
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Refining the treatment of NSCLC according to histological and molecular subtypes
- (2015) Anish Thomas et al. Nature Reviews Clinical Oncology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
- (2015) Nikolaos Patsoukis et al. Nature Communications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity
- (2015) Tong Seng Lim et al. OncoImmunology
- CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
- (2015) Margaret K. Callahan et al. Frontiers in Oncology
- Modulation of Immune Cell Functions by the E3 Ligase Cbl-b
- (2015) Christina Lutz-Nicoladoni et al. Frontiers in Oncology
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- (2014) C. Lebbe et al. ANNALS OF ONCOLOGY
- Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
- (2014) George C. Prendergast et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
- (2014) Yanping Xiao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- OX40- and CD27-Mediated Costimulation Synergizes with Anti–PD-L1 Blockade by Forcing Exhausted CD8+T Cells To Exit Quiescence
- (2014) Sarah L. Buchan et al. JOURNAL OF IMMUNOLOGY
- Acquired and intrinsic resistance in cancer immunotherapy
- (2014) Sander Kelderman et al. Molecular Oncology
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
- (2014) Magdalena Paolino et al. NATURE
- Entering the mainstream of cancer treatment
- (2014) Steven A. Rosenberg Nature Reviews Clinical Oncology
- Can we safely target the WNT pathway?
- (2014) Michael Kahn NATURE REVIEWS DRUG DISCOVERY
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune checkpoints in cancer clinical trials
- (2014) Elad Sharon et al. Chinese Journal of Cancer
- Highlights of the Latest Advances in Research on CDK Inhibitors
- (2014) Jonas Cicenas et al. Cancers
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
- (2013) Juliano D. Paccez et al. INTERNATIONAL JOURNAL OF CANCER
- Treg and CTLA-4: Two intertwining pathways to immune tolerance
- (2013) Lucy S.K. Walker JOURNAL OF AUTOIMMUNITY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
- (2013) M K Asiedu et al. ONCOGENE
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
- (2013) S. Viaud et al. SCIENCE
- B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence
- (2012) Tai-Wei Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
- (2012) M. Platten et al. CANCER RESEARCH
- PD-1 is a novel regulator of human B-cell activation
- (2012) Marie-Laure Thibult et al. INTERNATIONAL IMMUNOLOGY
- PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines
- (2012) Bingbing Dai et al. MOLECULAR THERAPY
- The human microbiome: at the interface of health and disease
- (2012) Ilseung Cho et al. NATURE REVIEWS GENETICS
- PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection
- (2012) Sonia Norris et al. VIRAL IMMUNOLOGY
- Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors
- (2012) Aung Naing et al. Journal of Cancer
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- Prospects for TIM3-Targeted Antitumor Immunotherapy
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
- (2011) Zahra Hanaizi et al. EUROPEAN JOURNAL OF CANCER
- Mechanisms of drug resistance in kinases
- (2011) Rina Barouch-Bentov et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Activation of the Canonical Wnt/β-Catenin Pathway in ATF3-Induced Mammary Tumors
- (2011) Leqin Yan et al. PLoS One
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Epigenetic disruption of the WNT/ß-catenin signaling pathway in human cancers
- (2010) Ying Ying et al. Epigenetics
- Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents
- (2010) S. Kundu et al. JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical importance of B7-H3 expression in human pancreatic cancer
- (2009) I Yamato et al. BRITISH JOURNAL OF CANCER
- Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
- (2009) Bryan T. MacDonald et al. DEVELOPMENTAL CELL
- Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
- (2009) Kim Kramer et al. JOURNAL OF NEURO-ONCOLOGY
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
- Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade
- (2008) S. D. Blackburn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started